ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2445

Dermatomyositis and Pregnancy: Assessment of Disease Activity and Pregnancy Outcomes Complicated By Maternal Dermatomyositis

Gopika Miller1, Elizabeth Moore2, Antonia Valenzuela3, Lorinda Chung4 and Victoria P. Werth5, 1Medicine, Harbor UCLA Medical Center, Torrance, CA, 2Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 4Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 5Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Dermatomyositis and pregnancy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Reproductive Issues in Rheumatic Disorders - Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The effect of pregnancy on Dermatomyositis (DM) disease activity and on maternal and fetal outcomes in patients with DM is unclear. Study objective is to evaluate disease activity and pregnancy outcomes complicated by maternal dermatomyositis.

Methods: A total of 10 patients with 21 pregnancies from a cohort of 438 DM patients of child-bearing potential, diagnosed between 2006 and 2015 from two centers, were eligible for interview with a specific questionnaire regarding pregnancy and fetal outcomes.

Results: Weakness, rash and arthritis were the most common clinical symptoms that improved during pregnancy in affected patients (Figure 1). In 16 out of 18 pregnancies, patients experienced weakness. Weakness improved during 13 pregnancies (81.3%), stayed the same during 2 pregnancies (12.5%), and worsened during one (6.3%). All 10 patients experienced cutaneous rash during all 18 pregnancies carried to live birth. Cutaneous rash improved during 13 pregnancies (72.2%), remain unchanged during 3 (16.7%), and worsened during 2 (11.1%). Five patients experienced arthralgias or arthritis in a total of 11 pregnancies. Symptoms improved during 10 of these pregnancies (91%) and worsened during one (9%).There were no cases of interstitial lung disease, cancer or antiphospholipid antibody syndrome among the 10 patients studied. One patient suffered from pre-eclampsia while diagnosed with DM. 3 total pregnancy losses: two early miscarriages (< 10 weeks gestation) one therapeutic abortion for an ectopic pregnancy. 3 neonates out of 18 live births went to the NICU after delivery – reasons for transfer: meconium aspiration; apnea and pre- term birth.

Conclusion: Pregnancy does not appear to carry a worse prognosis for DM patients and all but one of our patients experienced improvement in clinical symptoms during pregnancy.


Disclosure: G. Miller, None; E. Moore, None; A. Valenzuela, None; L. Chung, None; V. P. Werth, None.

To cite this abstract in AMA style:

Miller G, Moore E, Valenzuela A, Chung L, Werth VP. Dermatomyositis and Pregnancy: Assessment of Disease Activity and Pregnancy Outcomes Complicated By Maternal Dermatomyositis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/dermatomyositis-and-pregnancy-assessment-of-disease-activity-and-pregnancy-outcomes-complicated-by-maternal-dermatomyositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dermatomyositis-and-pregnancy-assessment-of-disease-activity-and-pregnancy-outcomes-complicated-by-maternal-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology